Doç. Dr. Heves Sürmeli
Is this your profile? Claim it and verify your details.
Claim profilePerson ↔ Disease
Which diseases does this doctor work on?
-
Breast Neoplasms 7 publicationsSource: OpenAlex / PubMed MeSHView publications
- Lung Neoplasms 3 publications
- Colorectal Neoplasms 3 publications
- Adenocarcinoma 3 publications
- Colonic Neoplasms 2 publications
- Carcinoma, Non-Small-Cell Lung 2 publications
- Carcinoma, Renal Cell 2 publications
- Kidney Neoplasms 2 publications
- Adenocarcinoma, Mucinous 2 publications
Person ↔ Disease
Which topics does this doctor work on?
Medical areas of interest stated by the doctor on the institution profile. Source: hisarhospital.com.
- Jinekolojik maligniteler
- Akciğer Kanseri
- Meme Kanseri
- Gastrointestinal Sistem Kanserleri
- Ürolojik Kanserler
CV
Education and experience
Doç. Dr. Heves Sürmeli, 1996-2004 yılları arasında Osmangazi Üniversitesi Tıp Fakültesi’nde Lisans eğitimini tamamlamıştır. 2005-2010 yılları arasında İstanbul Kartal Dr. Lütfi Kırdar Eğitim ve Araştırma Hastanesi’nde İç Hastalıkları uzmanlığını almıştır. 2014-2017 yılları arasında İstanbul Kartal Dr. Lütfi Kırdar Eğitim ve Araştırma Hastanesi’nde Tıbbi Onkoloji yan dal eğitimini tamamlamıştır.
İç Hastalıkları ve Tıbbi Onkoloji alanlarında çeşitli hastanelerde görev aldıktan sonra, 2017-2023 yılları arasında Kartal Dr. Lütfi Kırdar Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Kliniği’nde Tıbbi Onkoloji Uzmanı olarak hizmet vermiştir. 2023-2026 yılından itibaren aynı hastanede İdari Sorumlu / Klinik Sorumlusu olarak görev almıştır.
Uluslararası hakemli dergilerde yayınlanmış makaleleri ve bilimsel sunumları bulunmaktadır. Yurtiçinde ve uluslararası kongrelerde bildiriler sunmuş olup, alanında çeşitli dernek üyelikleri ve ödüllere sahiptir.
Education
- Education1996-2004hisarhospital.com
- EducationOsmangazi Üniversitesi Tıp Fakültesi – Lisanshisarhospital.com
- Education2005-2010hisarhospital.com
- Educationİstanbul Kartal Dr. Lütfi Kırdar Eğitim ve Araştırma Hastanesi – İç Hastalıkları Uzmanlıkhisarhospital.com
- Education2014-2017hisarhospital.com
- Educationİstanbul Kartal Dr. Lütfi Kırdar Eğitim ve Araştırma Hastanesi – Tıbbi Onkoloji Yan Dal Uzmanlıkhisarhospital.com
- Educationİdari Görevler:hisarhospital.com
- EducationKartal Dr. Lütfi Kırdar Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Kliniği İdari Sorumlu / Klinik Sorumlusu (2023–2026)hisarhospital.com
- EducationKartal Dr. Lütfi Kırdar Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Kliniği Uzmanı (2017–2023)hisarhospital.com
Trust
Where does this information come from?
The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.
- SpecialtyMedical Oncologyhisarhospital.comFrom source
- Department name at the sourceMedikal Onkolojihisarhospital.comFrom source
- InstitutionHisar Hospital Intercontinentalhisarhospital.comFrom source
- Area of workBreast NeoplasmsExtracted from 7 publications · Model version —From source
- Publications48 publicationsOpenAlex, ORCIDFrom source
- Languagesİngilizcehisarhospital.comFrom source
- ORCID0000-0003-1604-8466ORCIDFrom source
- Last synchronised4 November 2026 20:53https://hisarhospital.com/doktor/doc-dr-heves-surmelihisarhospital.com
Scientific work
Publications on Breast Neoplasms
-
Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study
Clinical Medicine Insights Oncology, 2026
DOI 10.1177/11795549261445290 PMID 42131419 Open-access full textSource: OpenAlex
-
Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide
Journal of Clinical Medicine, 2026
DOI 10.3390/jcm15010386 PMID 41517635 1 citation (Europe PMC) Open-access full textSource: OpenAlex
-
Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk–Stratified Analysis
Journal of Clinical Medicine, 2026
DOI 10.3390/jcm15051853 PMID 41827267 1 citation (Europe PMC) Open-access full textSource: OpenAlex
-
Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study
BMC Cancer, 2026
DOI 10.1186/s12885-026-16037-8 PMID 41987096 Open-access full textSource: OpenAlex
-
Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma
Journal of Cancer Research and Clinical Oncology, 2026
DOI 10.1007/s00432-025-06411-7 PMID 41504775 3 citations (Europe PMC) Open-access full textSource: OpenAlex
-
Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study
Medicina, 2026
DOI 10.3390/medicina62010099 PMID 41597386 1 citation (Europe PMC) Open-access full textSource: OpenAlex
-
Pan‑immune‑inflammation value as a prognostic and predictive biomarker in metastatic non‑small cell lung cancer treated with nivolumab: A real‑world study
Oncology Letters, 2026
DOI 10.3892/ol.2026.15750 PMID 42491228 Open-access full textSource: ORCID
-
Prognostic Value of the Cancer Inflammation Prognostic Index (CIPI) in De Novo Metastatic Colon Cancer: A Multicenter Retrospective Cohort Study
Cancer Control, 2026
DOI 10.1177/10732748261432273 PMID 41779425 Open-access full textSource: ORCID
-
Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage
Journal of Clinical Medicine, 2025
DOI 10.3390/jcm14197103 PMID 41096183 4 citations (Europe PMC) Open-access full textSource: OpenAlex
-
Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study
Journal of Personalized Medicine, 2025
DOI 10.3390/jpm16010008 PMID 41590501 3 citations (Europe PMC) Open-access full textSource: OpenAlex